SAN DIEGO, Oct. 14, 2015 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the 14th Annual BIO Investor Forum on October 21, 2015 at 9:00 a.m. Pacific time (12:00 p.m. Eastern time). The conference is being held at Parc 55 San Francisco hotel in San Francisco.
A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.
About BIO Investor Forum
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations and One-on-One Partnering™ meetings.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated assays for prostate cancer and other solid tumors in the near term. For additional information, please visit www.biocept.com.
SOURCE Biocept, Inc.